Requirement for matrix metalloproteinase-9 (Gelatinase B) expression in metastasis by murine prostate carcinoma

American Journal of Pathology

Volumn 152, Issue 2, 1998, Pages 591-596

  Sehgal, Geeta ^a   Hua, Jin ^a   Bernhard, Eric J ^a   Sehgal, Inder ^b   Thompson, Timothy C ^b   Muschel, Ruth J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PHORBOL 13 ACETATE 12 MYRISTATE; RIBOZYME; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME REPRESSION; MALE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANIMALS; CARCINOMA; COLLAGENASES; FEMALE; GELATINASES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RNA, CATALYTIC; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031930324     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Thompson T, Southgate J, Kitchener, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989, 56:917-930
2. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G: Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995, 10:869-879
3. Sehgal I, Baley PA, Thompson TC: Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer derived cell lines in vitro. Cancer Res 1996, 56: 3359-3365
4. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996, 7:147-154
5. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB, Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993, 53:417-422
6. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995, 7:728-735
7. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994, 33: 14109-14114
8. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, et al: Matrix metalloproteinases and processing of pro-TNF-α. J Leukocyte Biol 1995, 57:774-777
9. Sires, U., Griffin, G., Broekelmann, T., Mecham, R., Murphy, G., Chung, A., Welgus, H., and RM, S.: Degradation of entactin by matrix metalloproteinases. J Biol Chem 1993, 268:2069-2074
10. Tanaka H, Hojo K, Yoshida H, Yoshioka T, Sugita K: Molecular cloning and expression of the mouse 105-kd gelatinase cDNA. Biochem Biophys Res Commun 1993, 190:732-740
11. Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K: High expression of 92 kd type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 1994. 124: 1091-1102
12. Toth M, Gervasi DC, Fridman R: Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res 1997, 57:3159-3167
13. Ogata Y, Itoh Y, Nagase H: Steps involved in activation of the promatrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995, 270:18506-18511
14. Ogata Y, Enghild J, Nagase H: Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992, 267:3581-3584
15. Shapiro SD, Fliszar CJ, Broekelmann TJ, Mecham RP, Senior RM, Welgus HG: Activation of the 92-kd gelatinase by stromelysin and 4-aminophenylmercuric acetate: differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem 1995, 270:6351-6356
16. Desrivieres S, Lu H, Peyri N, Soria C, Legrand Y, Menashi S: Activation of the 92 kd type IV collagenase by tissue kallikrein. J Cell Physiol 1993, 157:587-593
17. Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995, 55: 2548-2555
18. Sang QX, Birkedal-Hansen H, Van Wart HE: Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta 1995, 1251:99-108
19. Atkinson SJ, Ward RV, Reynolds JJ, Murphy G: Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. Biochem J 1992, 288: 605-611
20. Willenbrock F, Crabbe T, Slocombe P, Sutton C, Docherty A, Cockett M, O'Shea M, Brocklehurst K, Phillips I, Murphy G: The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993, 32:4330-4337
21. O'Connell J, Willenbrock F, Docherty A, Eaton D, Murphy G: Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem 1994, 269:14967-14973
22. Strongin A, Collier I, Krasnov P, Genrich T, Marmer B, Goldberg G: Human 92 kd type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 1993, 43:158-162
23. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL: Interaction of 92-kd type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992, 267:4583-4591
24. DeClerck YA, Imren S: Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994, 30A:2170-2180
25. Yang TT, Hawkes SP: Role of the 21-kd protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci USA 1992, 89:10676-10680
26. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP: A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem 1992, 267:17321-17326
27. Howard EW, Bullen EC, Banda MJ: Preferential inhibition of 72-and 92-kd gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 1991, 266:13070-13075
28. Howard EW, Banda MJ: Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kd gelatinase: identification of a stabilization site. J Biol Chem 1991, 266:17972-17977
29. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996, 271:30375-30380
30. Leco KJ, Apte SS, Taniguchi GT, Hawkes SP, Khokha R, Schultz GA, Edwards DR: Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997, 401:213-217
31. Murphy G, Willenbrock F: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995, 248:496-510
32. Bernhard E, Muschel R, Hughes E: 92 kd gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 1990, 50:3872-3877
33. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994, 54:3260-3266
34. Bernhard E, Hagner B, Lubensky I, Wong C, Muschel R: The effect of E1A transfection on MMP-9 expression and metastatic potential. Int J Cancer 1995, 60:718-724
35. Hua J, Muschel RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996, 56:5279-5284
36. Muschel R, Williams J, Lowy D, Liotta L: Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol 1985, 121:1-8
37. Bernhard E, Gruber S, Muschel R: Direct evidence linking MMP-9 (92 kd gelatinase/collagenase) expression to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994, 91: 4293-4297
38. Meyuhas O, Perry RP. Construction and identification of cDNA clones for mouse ribosomal proteins: applications for the study of r-protein gene expression. Gene 1980, 10:113-129
39. Maity A, McKenna WG, Muschel RJ: Posttranscriptional regulation of cyclin B1 mRNA through the cell cycle and after irradiation. EMBO J 1994, 14:603-609
40. Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH: Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol 1992, 43:79-85
41. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME: In situ hybridization studies of metalloproteinases 2, and 9, and TIMP-1, and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997, 15:246-58
42. Festuccia C, Bologna M, Vicentini C, Tacconelli A, Miano R, Violini S, Mackay AR: Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996, 69:386-393
43. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL, Rees RC: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994, 69:177-182
44. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991, 117:144-150
45. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC: Elevated transforming growth factor-β1 and β3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 1991, 5:503-513
46. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER: Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 1994, 135: 2240-2247
47. Glynne-Jones E, Harper ME, Goddard L, Eaton CL, Matthews PN, Griffiths K: Transforming growth factor β1 expression in benign and malignant prostatic tumors. Prostate 1994, 25:210-218
48. Merz VW, Arnold AM, Studer UE: Differential expression of transforming growth factor-β1 and β3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer. World J Urol 1994, 12:96-98
49. Eklov S, Funa K, Nordgren H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S: Lack of the latent transforming growth factor β binding protein in malignant, but not benign prostatic tissue. Cancer Res 1993, 53:3193-3197
50. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C: Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 1996, 56:44-48